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Since the commercialization and ubiquitous use of antibiotics in the 20th
century, there has been a steady increase in the number of reports on resis-
tant bacteria. In recent years, this situation has become even more dramatic.
The relatively slow development of new drugs, especially those with novel
modes of action on target bacteria, is not paired with the rapid rate of resis-
tance appearance. Lantibiotics form a group of antimicrobial peptides of bac-
terial origin with a dual mechanism of action not shared by other therapeutic
compounds in use. They have a high potency to inhibit diverse (multidrug
resistant) bacteria, combined with a low tendency to generate resistance.
These properties make lantibiotics attractive candidates for clinical applica-
tions. This paper discusses some of the most recent results obtained in lantibi-
otic clinical application, paying special attention to the pharmacokinetic and
pharmacodynamic properties they display. The objective of this paper is to
give insight into the actual clinical applicability of lantibiotics and to point
to the unexplored aspects that should be addressed in future research.
The authors feel that lantibiotics could increase the number of second line
antibiotics for systemic use in the future; however, further research is still
needed before this is possible.
Keywords: lantibiotics, medical application, multidrug resistance, novel antibiotics,
pharmacodynamics, pharmacokinetics
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1. Introduction
The occurrence of multidrug-resistant microorganisms in the clinical environment
is continuously increasing over time. This problem has got worse with the appear-
ance of community acquired multidrug-resistant bacteria. Alarmingly, the discovery
of new antimicrobial agents is outpaced by the occurrence of new resistance mech-
anisms, underpinning the need for new antimicrobial compounds, especially those
with new modes of actions [1]. Lantibiotics are ribosomally synthesized antimicro-
bial compounds of bacterial origin containing modified amino acids, most notably
dehydrated amino acids and lanthionines and methyl-lanthionines from which their
name originates [2,3]. They are promising candidates to increase the number of avail-
able substances for treatment of bacterial infections. Lantibiotics interfere with cell
wall synthesis by interacting with lipid II, sequestering it from its location, that is,
the sites of cell wall synthesis. Moreover, some lantibiotics are able to insert into
the bacterial membrane after the interaction and create pores [4].
In this paper we will give an overview of the publicly available pharmacokinetic
and pharmacodynamic data on lantibiotics. While there are still important gaps
in the current knowledge that should be addressed (as discussed later), the feasibility
of applying lantibiotics as antibiotics is discussed in the expert opinion section.
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2. Lantibiotics versus antibiotics
Nisin, the first lantibiotic described and the most extensively
used around the world, was identified, as was penicillin, in
1928. Due to its peptide nature it initially did not draw a
lot of attention from the scientific community. With the
development of molecular biology techniques and the dis-
covery of its ribosomal synthesis (which enables peptide engi-
neering) and peptide modification techniques, lantibiotics
attracted renewed interest. Peptide engineering studies report
the creation of improved lantibiotics in terms of physico-
chemical properties and activity [5-8]. Lantibiotics have high
heat and protease resistance but their low stability at neutral
or high pH can be a problem for specific applications. Nisin,
for instance, is inactivated at neutral and basic pH values
and only a few lantibiotics (e.g., haloduracin) are stable at
pH > 7. Lantibiotics (1800 ~ 4600 g/mol) have a significantly
higher molecular mass than antibiotics (138 -- 1908 g/mol)
(Figure 1).
Lantibiotics and antibiotics display activity against bacteria
at similar concentration ranges (Table 1). The activity range of
lantibiotics against Gram negative bacteria is modest com-
pared to antibiotics with the exception of glycopeptide antibi-
otics. However, certain Gram negative species of Neisseria
and Moraxella are very sensitive to lantibiotics such as micro-
bisporicin [9]. Since antibiotics are in clinical use the preva-
lence of resistance against them is rising. Although it is
difficult to compare this feature with lantibiotics, nisin has
been used in food for the last 40 years and up to now no sig-
nificantly resistant bacteria have been observed [10]. Resistance
has been achieved in laboratory conditions using sub-
lethal concentrations of lantibiotics and has been accounted
to physiological changes rather than genetic alterations
although some authors have also referred a stable threefold
increase in MIC to some lantibiotics [11]. Innate resistance in
Listeria monocytogenes to nisin or gallidermin has been
studied and is related mainly with the presence of diverse
transporters, penicillin-binding proteins and an increase in
the number of positive charges present in teichoic acid
and phospholipids. This is a general response when
coping with membrane-active antimicrobials not specific for
lantibiotics [12].
Like the antibiotic vancomycin many lantibiotics target
lipid II, which is essential for bacterial cell wall synthesis.
Stable vancomycin resistant strains occur but they are still sus-
ceptible to lantibiotics, which interact with a different part of
lipid II, that is, the pyrophosphate moiety.
The ranges of applications for medical purposes that are
under study are quite similar to those of antibiotics with the
exception of CNS infections (Table 2) for which no reports
exist to our knowledge. Lantibiotics are specially promising
for treating skin and mucosal infections. Nisin has been tested
in mastitis in humans with high success and moreover due to
its peptide nature and low toxicity it does not require stopping
lactation [13].
Discovery of new naturally occurring lantibiotics can be
greatly facilitated by (automated) screening genetic databases
due to the fact that lantibiotics are ribosomally synthesized,
which is more difficult for antibiotics as they are not directly
genetically encoded [14,15].
3. Pharmacokinetic and pharmacodynamic
studies on lantibiotics
3.1 Administration
Due to their peptidic nature systemic application of lanti-
biotics would require parenteral invasive administration as
do glycopeptide antibiotics. Although oral administration is
not suitable for systemic applications, it is suitable for local
applications. Using specialized tablets Ugurlu et al. were
able to deliver nisin to specific parts of the gut [16]. Other local
administration routes as intravaginal, dermic or inhaled forms
can be used to achieve local effect as only very low absorption
is detected [17-20].
3.2 Distribution
Lantibiotics strongly bind plasma proteins and can also
bind to blood cells. Mutacin 1140, for instance, is bound to
blood components to a high degree (92.7% bound) lowering
the available active molecule [21] Therefore, a model describ-
ing the pharmacokinetic and pharmacodynamic parameters
of mutacin 1140 could only be fitted to the experimental
data after the addition of an open second compartment
(the plasma proteins) [17]. Next to this, the interaction
between this lantibiotic and blood components can change
the activity against a specific strain [21] This implies that
special considerations must be taken for dosage studies in
order to achieve an effective lantibiotic concentration at the
site of infection.
3.3 Metabolism and excretion
Only few reports on the fate of lantibiotics in mammals exist.
According to McNulty et al. duramycin is not modified prior
to excretion [22]. In vitro experiments have shown their
increased resistance to proteases due to the presence of
lanthionines and methyl-lanthionines. The only elimination
studies performed in vivo refer to duramycin applied as aero-
sol in the lung or in the nose. In these cases it is mainly
excreted in feces due to lung mucus removal and swallowing.
Available data of elimination rates between animal and
human are quite different, thus requiring a more thorough
study [18,19,23]. The renal elimination rate of duramycin
depends on its binding to serum [21]. Duramycin administered
intravenously to mice and rats accumulates mainly in the
liver; it is excreted renally and has a relatively long half-life
of ~ 5 days [22].
3.4 Toxicity of lantibiotics
In vitro toxicity studies using diverse epithelial cell lines
only show low toxicity after lantibiotic treatment, thus
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encouraging in vivo experiments [24,25]. While testing nisin,
which was mucosally applied in an animal model, researchers
did not detect any immune response, noted no other visible
symptoms and found that the cytokine levels were not
altered [24]. Feeding rats a diet containing £ 5% nisin showed
no measurable toxicological effects [26]. Some toxic effects
have been shown to be caused by contaminants in the nisin
preparation, which disappear when using HPLC purified
nisin [27]. Most lantibiotics are only hemolytic at high con-
centrations (nisin: 175 mg/l) [25] with the exception of cytoly-
sin, a two-component lantibiotic from Enterococcus faecalis,
which is highly hemolytic [28]. Also it has been shown that
subtle changes in amino acid composition can convert a
non-hemolytic lantibiotic into a hemolytic one [29].
The teratogenic potential of nisin was investigated with no




Figure 1. Comparison of the structures of nisin (from pdb ID: 1UZT: doi:10.2210/pdb1wco/pdb) with ampicillin (from
pubchem database CID_6249), a beta-lactam antibiotic, and vancomycin (pdb ID: 1C0R; doi:10.2210/pdb1c0r/pdb), a
glycopeptide antibiotic. The image was made using pymol (version 1.3), the hydrogen atoms are not displayed.





Nisin A Vancomycin Oxacillin
Gram-positive
Enterococcus spp. 12.8 16.7 3.9 11.9
Staphylococcus spp. 1.6 4.2 3.8 7.9
Streptococcus spp. 0.4 8.4 0.5 0.1
Clostridium spp. 0.2 1.1 0.5 1.1
Gardnerella vaginalis 0.03 1.1 0.4 0.1
Mycobacterium smegmatis 32 8.4 8.0 95.1
Propionibacterium acnes 1.2 2.1 1.0 0.5
Gram-negative
Helicobacter pylori 0.07 0.3 1.0 0.5
Neisseria spp. 1.6 8.4 30.1 11.2
Haemophilus influenzae 13 66.9 > 120 63.4
Campylobacter jejuni 0.07 1.1 1.0 0.1
Multidrug resistant organisms
N. gonorrhoeae 013x (OxaR) 1.6 4.2 30.1 127
N. gonorrhoeae 022 (VanR) 3.2 12 60 32.7
N. gonorrhoeae INF2 (OxaR VanR) 2.3 8.4 60.2 31.7
E. faecalis 2 L.5.07 (OxaR) 6.4 8.4 1.9 31.7
E. faecalis EF-Chul (OxaR VanR) 6.4 8.4 > 120 10.2
S. aureus R678 (OxaR) 3.2 8.4 2.7 15.9
S. aureus R650 (OxaR) 3.2 8.4 3.8 44.8
Multidrug-resistant bacteria are at least resistant to four different antibiotics.
Adapted from [38] with permission of the American Society for Microbiology.
OxaR: Oxacillin resistant; VanR: Vancomycin resistant.
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animals [27]. Interestingly nisin has been investigated as a con-
traceptive agent because of its spermicidal activity [30,31]. This
is only observed at high concentrations and is selective for
spermatozoa due to their special membrane composition [32].
No differences were observed in the blood parameters and his-
tological samples of animals topically treated with nisin and
duramycin compared to an untreated control [19,23,24,27,33].
Humans treated with aerosolized duramycin also showed no
differences in their blood parameters after treatment [34].
Furthermore, it has been reported that rapid infusion of
mutacin 1140 in rats causes reversible hypersensitivity reac-
tions that can be blocked using diphenhydramine prior to
the treatment [17].
In conclusion the toxicological data sets a limit to the
therapeutical window that is broad enough to encourage fur-
ther research. Hemolytic activity of lantibiotics appears to be
unpredictable and should, therefore, be individually assessed.
4. Expert opinion
Lantibiotics constitute a family of very stable ribosomally syn-
thesized peptides amenable to molecular engineering with
high antimicrobial potency, comparable to that of conven-
tional antibiotics. Their unique mechanism of action and
their low propensity to generate resistance are attractive prop-
erties of these compounds. Until now research in lantibiotics
has focused on bio-engineering to improve activity, to investi-
gate the structure-activity relationship and to understand the
modification process. It is now time to focus more on clinical
aspects of lantibiotics. Although important knowledge has
been acquired, as discussed in this paper, some questions
remain unanswered.
Lantibiotics show low absorption rates thus enabling local
delivery. This could represent one advantage minimizing their
effect on normal microbiota somewhere else in the organism
and reducing the dose. Systemic applications would require
invasive parenteral administration, but for this some hurdles
have to be taken. First of all, the bio-availability can be a
problem especially since some lantibiotics have a high affinity
to blood components. Second, most lantibiotics are not very
stable at physiological pH. Although we do not anticipate
problems arising from the hemolytic activity of lantibiotics,
it can only be excluded to form a problem once more data
that relate dosage to effectiveness are available [35]. Lanti-
biotics do not significantly affect organs, tissues or blood
parameters in animals. In humans similar results indicate the
safety, but so far the number of participants in these studies
is low and, therefore, rare adverse effects cannot be discarded.
In our opinion it is necessary to evaluate the in vivo concen-
tration of a given lantibiotic and its elimination rate. With
this data, dosage regimes that can be compared to concentra-
tions needed for effective therapeutic use can be established.
This will allow, in addition, a more precise toxicological
study at therapeutic concentrations with time. These data
can also be used to define which properties need to be
improved on by protein engineering (i.e., stability or solubi-
lity). In parallel, pharmaceutical technology can provide the
tools to circumvent these problems.
Local applications of lantibiotics look very promising also to
potentially fight re-occurring infections. The work conducted
on microbisporicin and nisin to treat Clostridium difficile and
Staphylococcus aureus infections, respectively, is especially
encouraging [36,37]. Lantibiotics could extend the number of
second-line antibiotics for systemic use in the future, provided
the open questions mentioned here can be answered.
Declaration of interest
All of the authors are supported by the University of
Groningen. Additionally OKuipers is supported by the Kluyver
Centre while AJ van Heel is supported by the Netherlands
Organization for Scientific Research STW Technology founda-
tion GenBiotics project. M Montalban-Lopez is supported by
the European Research Foundation’s EuroSYNBIO program.
Table 2. Clinical trials and (pending) patents involving lantibiotics.
Lantibiotic and commercial name(s) Purpose Ref.
Clinical trials
Duramycin/Moli1901/Lancovutide/2622U90 Phase II placebo-controlled, double-blinded,
single-center study of the safety of nebulized







Treatment of halitosis [40]
BLIS (salivaricins) Acne treatment [41]
Mersacidin Skin and systemic infection [42]
Nisin Bovine mastitis [43]
Nisin Oral cavity applications [44]
Mutacin producing S. mutans Replacement therapy for caries [45]
Nisin and lantibiotic combinations Skin infection treatment [37]
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